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Abstract: Genome editing tools, such as TALEN (transcription activator-like effector nuclease) or CRISPR-Cas9 (CRISPR-associated protein-9 
nuclease) systems, enable functional studies by targeted gene knockout. They introduce double-stranded breaks (DSBs) into a DNA molecule 
in a sequence-specific manner, thereby stimulating the error-prone non-homologous end joining repair mechanism, leading to probable gene 
inactivation when the coding sequence is targeted. Vectors for expression of TALEN and Cas9-based constructs targeting the human IL6ST and 
HNF1A genes were assembled and tested for their ability to introduce DSBs when transfected into cultured cells using the luciferase assay. The 
Cas9-based construct targeting the IL6ST gene was shown to be active, while the two TALEN-based constructs did not introduce DSBs above 
background level. Both the TALEN and the CRISPR-Cas9 constructs targeting the HNF1A gene were found to be active, with the TALEN showing 
higher activity in a dose-dependent manner. The constructed genome-editing tools can be used for functional analysis of the putative role of 
HNF1A and IL6ST genes in IgG glycosylation, as shown previously by genome wide association studies. 
 





ENE knockout using site-specific nucleases has 
opened new possibilities for functional studies of 
gene function. Chimeric nucleases, composed of program-
mable sequence-specific modules and DNA cleavage 
domains, can be used to introduce single (nick) or double-
stranded breaks (DSBs) at the targeted site, thus 
stimulating error-prone non-homologous end joining 
(NHEJ) or homology-directed repair (HDR).[1] The breaks 
then stimulate either knockout or homology-based 
insertion at specific loci. They can be applied both in 
cultured cells and in a whole organism.[2,3] Those actions 
have been termed genome editing or genome engineering. 
 A successful genome editing tool must perform two 
essential functions: targeting to a specific DNA sequence 
and cleavage of one or both strands of the DNA molecule. 
There are several targeting systems possessing different 
complexity, specificity, modularity, ease of assembly and 
sensitivity to DNA methylation. Homing nucleases 
(extensively reviewed by Stoddard)[4] were among the first 
enzymes of prokaryotic origin that were used for 
modifications of the genome. They recognize, bind and 
cleave specific DNA sequences (20 to 30 bp long) unlikely to 
be found in a genome by chance alone. In some cases they 
were successfully engineered to target novel sequences by 
altering their DNA-contacting residues.[4] Another step in 
flexibility and modularity of targeting were the zinc finger 
nucleases (ZFNs), consisting of zinc finger protein motifs 
assembled to bind the desired sequence and the FokI 
nuclease for cleavage of DNA.[5] Additional specificity is 
conferred by the requirement for dimerization of two FokI 
subunits, which need to be aligned by targeting two 
appropriately spaced sequences in opposite orientations.[5] 
 Transcription activator-like effectors (TALE) are pro-
teins naturally occurring in the plant pathogen 
Xanthomonas, where they bind DNA via a domain of 
tandem repeats.[6] These repeats bind specific nucleotides 
according to amino acids at two key positions (repeat-
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repeats enables efficient assembly of targeting domains 
fused with the FokI nuclease. The pair of TALE nucleases 
(TALENs)[7] introduces double-stranded breaks at the 
targeted site in a manner similar to ZFNs, but with the 
advantages of highly predictable modular assembly and the 
possibility of targeting almost any DNA sequence. Plasmid 
kits containing RVD-encoding sequences and appropriate 
TALEN backbones[7,8] have made the TALEN technology 
widely available. Compatible backbones enable harnessing 
the additional specificity conferred by engineered 
heterodimeric FokI domains.[9] 
 Another prokaryotic DNA-binding system repurposed 
for genome engineering is the CRISPR-Cas9, which is based 
on the endonuclease Cas9 guided by a short RNA molecule 
that defines the binding specificity.[10] Co-expression of the 
Cas9 protein with a 20 bp single guide RNA (sgRNA) enables 
targeting to any DNA sequence followed by the protospacer 
adjacent motif (PAM) NGG, which occurs on average every 
8–12 bp in the human genome.[11] This system enables easy 
programming of Cas9 specificity and even allows multiple 
targeting by co-expression of several sgRNAs, which can be 
quickly and conveniently cloned into a dual-expression 
vector (Cas9 and sgRNA) by oligo annealing.[12] 
 Gene knockout by TALEN or Cas9-based systems 
depends on introduction of double-stranded breaks (DSBs) 
into the reading frame of the targeted gene. Those DSBs are 
repaired by the error-prone NHEJ mechanism, which 
introduces short insertions or deletions potentially leading to 
frameshift mutations, thus abolishing gene function. In order 
to generate successful biallelic knockouts, it is useful to select 
the most efficient TALEN or CRISPR-Cas9 constructs by 
testing their ability to introduce DSBs at the targeted region 
in vivo. An elegant assay based on luciferase reporter plasmid 
has been developed by Porro and coworkers.[13] The 
luciferase reporter plasmid drives expression of the firefly 
luciferase gene interrupted by a multiple cloning site (MCS) 
flanked by two 548 bp repeated regions of luciferase cDNA. 
The sequence targeted by genome editing tools is cloned  
into the MCS and upon co-transfection, homologous 
recombination between flanking repeats reconstitutes 
luciferase activity in proportion to the frequency of DSBs 
induced in the cloned targeted region. 
 The post-translational modification of eukaryotic 
proteins by glycosylation highly influences their structure 
and function. Protein glycosylation is involved in many key 
cellular and physiological processes,[14] and can furthermore 
provide a cell with a mechanism for rapid adaptation by 
integration of environmental information.[15] Large-scale 
genome-wide association studies (GWAS)[16,17] have recently 
identified many putative loci associated with protein 
glycosylation. Two of them, the HNF1A gene (encoding the 
hepatic nuclear factor alpha) and the IL6ST gene (the 
interleukin 6 signal transducer shared by many cytokines) are 
particularly interesting in our studies of epigenetic regulation 
of protein glycosylation in complex diseases. The HNF1A is 
shown to be a master regulator of plasma protein 
fucosylation.[16] Recently, we have shown that epigenetic 
silencing of HNF1A by methylation at several CpG sites within 
the promoter strongly correlates with highly branched 
glycans from plasma and that epigenetic silencing of this 
gene could be a mechanism leading to a subtype of diabetes 
(i.e. HNF1A-MODY).[18] On the other hand, the IL6ST has been 
associated both with immunoglobulin G (IgG) glycosylation 
and inflammatory and autoimmune conditions, such as 
inflammatory bowel disease (IBD),[17] which we are currently 
studying in terms of epigenetics and glycosylation.[19] 
 The aim of this work was to assemble several 
genome editing tools for knockout of human genes HNF1A 
and IL6ST and select the most efficient TALEN or CRISPR-
Cas9 construct for each gene using the luciferase assay. The 
most successful genome editing tools will be used for 
generation of cell lines with biallelic knockout and 
functional analyses of the role of the HNF1A and IL6ST 




TALEN Vector Construction 
A single TALEN target site in the HNF1A gene was 
selected using the Mojo Hand TALEN design tool 
(http://www.talendesign.org/classic/).[20] Two TALEN 
target sites located in different exons of the IL6ST gene 
were selected from the collection of TALENs previously 
designed to target every human protein-coding gene.[21] 
The plasmid kit used for generation of TALENs was a gift 
from Daniel Voytas and Adam Bogdanove (Addgene kit # 
1000000024).[7] The NN RVDs were used as guanine-
binding modules. TALE repeats for the HNF1A gene were 
assembled according to the original protocol.[7] The 
assembly of two IL6ST TALE repeats was conducted using a 
modified protocol involving intermediary 6-module pFUS 
array vectors.[8] These modified pFUS vectors can reduce 
the number of module plasmids and improve the success 
rate of Golden Gate assembly. The additional plasmid kit 
used for building TALENs and TALE-TFs was a gift from 
Takashi Yamamoto (Addgene kit # 1000000030). The 
assembled TALE repeats were cloned into heterodimeric 
FokI destination vectors pCAG-T7-TALEN(Sangamo)-FokI-
ELD-Destination (Addgene plasmid # 40132) and pCAG-T7-
TALEN(Sangamo)-FokI-KKR-Destination (Addgene plasmid 
# 40131), both of which were gifts from Pawel Pelczar.[9] 
Final constructs were confirmed by bidirectional Sanger 
sequencing of repeat arrays using primers TAL_F1 and 
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CRISPR-Cas9 Vector Construction 
The SpCas9 target sites in the HNF1A and IL6ST genes 
were selected from the list of suitable targets predicted 
using the CRISPR Design Tool (http://crispr.mit.edu/).[22] 
Pairs of oligonucleotides encoding sgRNA sequence were 
annealed and cloned between BbsI restriction sites of 
pX330-U6-Chimeric_BB-CBh-hSpCas9 expression vector 
using the established protocol.[12] The plasmid pX330-U6-
Chimeric_BB-CBh-hSpCas9 was a gift from Feng Zhang 
(Addgene plasmid # 42230). The sequence of cloned 
sgRNAs was verified by sequencing from the hU6_Seq_F 
primer. Sequences of overlapping oligonucleotides used 
for sgRNA cloning (IL6ST_pX330_S and IL6ST_pX330_A for 
IL6ST sgRNA; HNF1A_pX330_S and HNF1A_pX330_A for 
HNF1A sgRNA) and the sequencing primer are listed in 
Table 1. 
Generation of pGL3-IL6ST and pGL3-
HNF1A Luciferase Reporter Vectors 
Generation of pGL3-Linker vectors containing the target 
fragment was done essentially as described previously.[13] 
To generate the target sequence containing three binding 
sites for IL6ST-targeting nucleases, 548 bp fragment 
containing parts of exons 3, 7 and 12 from IL6ST cDNA 
flanked by BamHI restriction sites was synthetized (Blue 
Heron Biotech, WA, USA) and cloned into the pGL3-Linker 
BamHI site. The targeted IL6ST sequences (52 bp long for 
TALENs and 20 bp long for CRISPR-Cas9) were flanked by 
about 50 bp of their genomic context on either side, making 
them spaced about 100 bp relative to each other on the 
reporter plasmid. As all the HNF1A-targeting nucleases 
were directed to exon 1, a 552 bp fragment from exon 1 
was amplified by PCR with Herculase II Fusion proofreading 
DNA polymerase (Agilent Technologies, Santa Clara, CA, 
USA) and cloned into the EcoRV site of the pGL3-Linker 
plasmid. All constructs were verified by Sanger sequencing. 
Primers used for PCR of the HNF1A gene target (HNF1A_For 
and HNF1A_Rev) and for sequencing from the pGL3-Linker 
plasmid (RVprimer3) are listed in Table1. 
Transient Cell Transfection and Dual 
Luciferase Assay 
HEK293 cells were plated in 24-well plates in complete 
DMEM (supplemented with 10% FBS, 4 mM L-glutamine and 
100 U / mL–100 μg / ml Pen-Strep) 24 h prior to transfection. 
Cells were co-transfected in duplicates, at 50–70 % conflu-
ence with 40 ng of Renilla luciferase plasmid (phRG-TK, 
Clontech, Mountain View, CA, USA – for normalization of 
transfection efficiency), 400 ng of pGL3-Linker (negative 
control) or pGL3-IL6ST/pGL3-HNF1A plasmids and increasing 
amounts of nuclease (TALEN or Cas9) expressing plasmids 
(100 ng, 200 ng and 400 ng) using Lipofectamine 3000 
(Thermo Fisher Scientific, Waltham, MA, USA) according to 
manufacturer’s instructions. Five hours after transfection 
cells were washed in 1× PBS and fresh medium was added. 
 Cells were harvested 72 h following transfection and 
nuclease activity was determined by dual luciferase assay 
(Promega, Fitchburg, WI, USA). Briefly, cells were lysed with 
100 µL of 1× PLB (passive lysis buffer), incubated for 30 min 
at room temperature and centrifuged for 1 min at maxi-
mum speed. Firefly luciferase activity was determined by 
adding 30 µL of LAR II (luciferase assay reagent II) to 30 µL 
of the cell lysate. Subsequently, Renilla luciferase activity 
was determined by adding 30 µL of Stop & GLO substrate. 
Co-transfection with another plasmid expressing Renilla 
luciferase (phRG-TK) was used for normalization according 
to transfection efficiency. Luciferase activity was 
determined on a Fluoroskan Ascent luminometer (Thermo 
Fisher Scientific). 
 
RESULTS AND DISCUSSION 
Assembly of TALEN and CRISPR-Cas9 
Constructs for Knockout of the HNF1A 
and IL6ST Genes 
TALEN constructs were successfully assembled with correct 
RVDs cloned into the destination vector backbone, as 
confirmed by sequencing. TALEN pairs were constructed as 
heterodimers (ELD and KKR domains of FokI) to decrease 
non-specific activity.[9] CRISPR plasmids had the correct 
guide RNA sequence inserted at the appropriate site, which 
was verified by sequencing from the U6 promoter. The 
exact sites within the HNF1A and IL6ST genes which were 
targeted by the constructs are depicted in Figure 1. In order 
to prevent spurious binding and non-specific activity, all 
targeted sites were selected so that they are unique within 
Table 1. Sequences of oligonucleotides used for cloning, PCR 
or sequencing. 
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the human genome and sufficiently different from the 
next closest match. Constructs were targeted to the 5’ 
part of the coding sequence to disrupt the gene product 
activity, avoiding the possibility of a resulting truncated 
protein with residual activity. 
Activity Testing and Selection of 
Constructs Using Luciferase Assay 
Constructs targeting specific regions in the HNF1A and 
IL6ST genes were tested for their ability to introduce 
double-strand breaks (DSBs) in reporter plasmids when 
co-transfected in HEK293 cells. We did not expect any 
interference between endogenous targets in the 
genome and reporter plasmids because both the 
reporter vector and expressed constructs (Cas9 or 
TALEN proteins) were in large excess relative to genomic 
targets, as we observed in experiments with similar 
constructs using immunofluorescence and western 
blots.[23] In Figure 2, the activity is presented as 
normalized luminescence. Luminescence measurements 
 
Figure 1. Sequences within the HNF1A (A) and IL6ST (B) genes targeted by the genome editing tools. Boxes represent gene 
schematics with coordinates within the hg38 human genome assembly and relative positions of the exons. Arrowheads along 
the gene model point in the direction of the coding strand of the gene (HNF1A is on the [+] and IL6ST on the [–] strand of the 
genome assembly). Exon models (gray and blue horizontal bars with the exon number indicated) are drawn on the same scale 
for both genes and highlighted regions correspond to the targeted sequences. Exon models are always in the direction of the 
coding strand. Expanded view for each targeted site shows the exact sequence of the target site. For CRISPR constructs (the 
HNF1A exon 1 to the right and the IL6ST exon 12) the 20 nt sgRNA sequence which binds the target site is indicated in capital 
letters. The PAM sequence NGG is shown on the coding strand. Red triangles indicate the cleavage site. Other expanded models 
show TALEN pairs binding to their recognition sequence, which is indicated by capital letters. Two TALENs from a pair bind to 
opposite strands. Each TALEN binding sequence is preceded by a T nucleotide (indicated in red) at its 5’ end, which is necessary 
for proper interaction with the N-terminal part of the TALEN. RVDs are shown color-coded and aligned to the target sequence. 
The C-terminally fused FokI nuclease subunits ELD and KKR form an active heterodimer in the region between two facing TALEN 
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were in the range similar to the range reported in the 
study describing the luciferase assay,[13] which also 
reported a good correlation between the luciferase 
assay and in situ targeting. While TALEN-based construct 
could not induce DSBs above background level at the 
IL6ST targeted sites, the Cas9-based construct showed 
activity in a dose-dependent manner. Effectiveness was 
higher when lower amount of plasmid was transfected 
(100 ng) and decreased almost to the background level 
when the maximum amount (400 ng) of Cas9 plasmid 
DNA was used. This demonstrates the need for careful 
titration of the amount of construct used for 
transfection since too much plasmid might have an 
inhibitory effect on DSB generation activity. Constructs 
targeting the HNF1A gene both showed activity levels 
well above background (Figure 2). The TALEN pair 
showed higher activity when larger amounts of the 
plasmids were transfected. In contrast, the CRISPR-Cas9 
construct did not show a dose-dependent response. 
Given the increase in standard deviation with increasing 
concentration of the Cas9-based plasmid used for 
transfection, the lowest tested amount (100 ng) can be 
recommended for further experiments. 
CONCLUSION 
We have successfully constructed the Cas9-based and 
TALEN-based genome editing tools targeting the IL6ST and 
HNF1A genes. Targeted regions were selected at the 
beginning of the genes within the coding region in order to 
achieve the complete functional knockout once the biallelic 
DSBs were introduced successfully. 
 Based on the luciferase assay, we identified the 
Cas9-based construct as the most active for inducing DSBs 
in the IL6ST gene. Since activity was dose-dependent, we 
can recommend the lowest dose tested (100 ng) for 
HEK293 cells in our experimental setup. Both constructs 
targeting the HNF1A gene induced DSBs above the 
background level, with the TALEN pair showing stronger 
activity, especially when the cells were transfected with the 
larger amounts of plasmid. 
 We have demonstrated that our genome editing 
tools can efficiently induce DSBs in the targeted genes IL6ST 
and HNF1A. Those tools will be essential for our 
prospective functional studies of the role of these genes in 
plasma protein and IgG glycosylation, as well as their 
possible role in disease pathology via deregulated protein 
glycosylation pathways. 
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